We have some exciting news we thought you might be interested in hearing more about. If you are using next-generation sequencing (NGS) instrumentation, QIAGEN recently released 14 new GeneRead DNAseq V2 gene panels for use in next-generation sequencing (NGS) spanning a wide array of cancer and translational research applications. Even more exciting is that these new panels are pre-integrated directly with QIAGEN’s Ingenuity® Variant Analysis™, which combines analytical tools and integrated content to help you rapidly annotate, identify and prioritize a targeted set of compelling variants based both upon published biological evidence and your own knowledge of disease biology.
The GeneRead gene panels are compatible with any NGS sequencer and customizable to include other genes or gene regions of clinical or biological interest. Providing the most cost-effective and time-efficient approach for target enrichment using NGS, the panels use as little as 10 nanograms of starting DNA material per pool, require only three hours to enrich for targets and substantially reduce the time to go from isolated DNA sample to sequencing-ready libraries. They are compatible for use with FFPE samples, do not require specialized instruments, and achieve industry leading coverage (>96% of coding regions), specificity (>90% of reads on target) and uniformity (>90% of bases covered by at least 20% of the mean coverage depth).
After you’ve run the panels on your sequencer, the data can be analyzed via the QIAGEN NGS Data Analysis Web Portal which is where you can then upload your results directly to Variant Analysis. We’ve created a short video tutorial that shows you how this works.
As an introductory offer, every shipped GeneRead panel kit will include a free activation code for uploading GeneRead panel data into Variant Analysis.
This is one small way we are looking to bring together sample to insight based solutions that make it faster, easier, and more convenient for you to get high quality results from your research. Give it a try and let us know what you think.